2226212-40-2
2226212-40-2 structure
- Name: Talquetamab
- Chemical Name: Talquetamab
- CAS Number: 2226212-40-2
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2023-02-09 13:41:50
- Modify Date: 2025-12-04 15:37:20
-
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity[1][2].
| Name | Talquetamab |
|---|
| Description | Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Talquetamab (0.00128-4.0 μg/mL, 48 h) 有效诱导多发性骨髓瘤细胞裂解，并导致活化的 CD4+ 和CD8+ T 细胞比例显著增加，以及颗粒酶 B 和炎症细胞因子如 IL-6、IL-8 和 TNF-α 水平的剂量依赖性增加[1]. |
| In Vivo | Talquetamab (JNJ-64407564) (0.1-50 µg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性[2]。 Animal Model: Female NSG mice with H929 cells[2] Dosage: 0.1-10 µg (0.005 mg/kg) Administration: Subcutaneous injection; on days 0, 3, 5, 7, and 10 Result: Completely blocked tumor formation at 1 μg and 10 μg doses. Animal Model: Female NSG mice with human MM cells[2] Dosage: 0.1-50 µg (0.005 mg/kg) Administration: Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36 Result: Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression. |
| References |
| No Any Chemical & Physical Properties |